Description

Retatrutide is a triple-agonist peptide that targets GLP-1, GIP, and glucagon receptors, making it a powerful investigational compound in metabolic research. Clinical studies indicate its potential to significantly reduce body weight, improve glycemic control, reduce liver fat, and positively impact cardiovascular risk factors.
 
Key Research Highlights
 
Weight Loss: Up to 24.2% reduction in body weight over 48 weeks.
Liver Health: Over 85% of subjects reversed MASLD-associated liver fat thresholds.
Blood Sugar Control: HbA1c reductions up to 2.02% in type 2 diabetes studies.
Cardiometabolic Markers: Decreases in triglycerides, ApoC-III, and blood pressure.
 
Research Application: 
 
Route: Subcutaneous injection
Schedule: Once weekly
 
Titration Protocol (based on published studies):
 
Weeks 1–4: 2 mg
Weeks 5–8: 4 mg
Weeks 9–12: 6 mg
Weeks 13+: 8–12 mg based on protocol objectives
 
Availability:
 
Purity: ≥99%
Form: Lyophilized powder for reconstitution
 
Note: This is not an exhaustive risk or safety profile and reflects only limited published data.
 
The statements made on this website have not been evaluated by the US Food and Drug Administration. These are not findings from Raina's Summit, but instead publicly available studies. This product is for research purposes only and is not approved for human consumption or clinical use.